-
Mashup Score: 82023 Key Learnings in mCRPC Treatments – Alicia Morgans - 2 day(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Rana R. McKay, Medical Oncologist, Associate Professor,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi - 10 day(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Sumit K. Subudhi, Associate Professor, Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming - 11 day(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice – Mark Fleming Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Mark Fleming, MD, GU Disease Committee Chair, Sarah Connon Research Institute, President, Virginia Oncology…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 9
Jacob Orme and Emmanuel Antonarakis discuss their study on the use of PARP inhibitors in metastatic prostate cancer patients with BRCA2 and SPOP mutations. Dr. Antonarakis shares the study’s genesis, rooted in his clinical observation of exceptional responses to PARP inhibitors in patients with these mutations. The study, involving 131 patients across 13 international sites, reveals that…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 13PARP Inhibitor + AR Signaling Inhibitor Combos Improve mCRPC Outcomes in Meta-Analysis - Rashid Sayyid - 22 day(s) ago
Rashid Sayyid discusses a systematic review and meta-analysis on combining PARP inhibitors with AR signaling inhibitors in mCRPC treatment, published in BJU International. The study, which synthesized data from three significant trials, sought to improve survival across all patients, focusing on those without specific biomarkers. Results showed a 35% reduction in radiographic progression-free…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 82023 Key Learnings in mCRPC Treatments – Alicia Morgans - 1 month(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Rana R. McKay, Medical Oncologist, Associate Professor,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 9
Jacob Orme and Emmanuel Antonarakis discuss their study on the use of PARP inhibitors in metastatic prostate cancer patients with BRCA2 and SPOP mutations. Dr. Antonarakis shares the study’s genesis, rooted in his clinical observation of exceptional responses to PARP inhibitors in patients with these mutations. The study, involving 131 patients across 13 international sites, reveals that…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 7
Rashid Sayyid and Zach Klaassen discuss the updated AUA guidelines for advanced prostate cancer, focusing on metastatic castration-resistant prostate cancer (mCRPC). The guidelines emphasize the importance of baseline labs, metastatic disease location, and symptoms for prognosis and treatment decisions in mCRPC patients. Statement #25 highlights the significance of various lab markers and…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming - 2 month(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice – Mark Fleming Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Mark Fleming, MD, GU Disease Committee Chair, Sarah Connon Research Institute, President, Virginia Oncology…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi - 2 month(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Sumit K. Subudhi, Associate Professor, Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
2023 key learnings in #mCRPC Treatments. @CaPsurvivorship @DanaFarber joins @DrRanaMcKay @UCSanDiego in this discussion as part of an independent medical education initiative supported by @LoxoLillyOnc > https://t.co/oI9FiDH6C6 https://t.co/ToBIdPkU8Z